Korean J Urol.  1993 Jun;34(3):409-413.

Clinical significance of measurements of serum CA19-9 in genitourinary cancer

• Kang HJ
• Kim JC
• Rhew HY

Abstract

We measured serum CA19-9 from March 1990 to June 1992 in 63 cases of normal controls, 56 cases or bladder cancer, 32 cases of renal cell carcinoma, 8 cases of prostatic carcinoma, 4 cases of penile cancer. 2 cases of testicular cancer and 3 cases of carcinoma of gastrointestinal tract with metastasis to the retroperitoneum. The results of this study were that serum levels of CA19-9 in urinary bladder cancer, renal cell carcinoma and prostatic carcinoma were statistically significant. However, sensitivity was low, 14. 29% for urinary bladder cancer, 18.75% for renal cell carcinoma. 12.5 % for prostatic carcinoma and specificity was 95.2%. In renal cell carcinoma, there was no change in serum level between stages. However there was a statistically significant difference (p<0.05) between low stage(A, B) and high stage(C, D) urinary cancers. We suggest that serum CA19-9 levels cannot be used as a screening test or prognosis indicator in tumors of the genitourinary tract ; however it can be helpful in differentiating between low and high stage urinary bladder cancers.

Keyword

CA19-9; Genitourinary tract tumor

MeSH Terms

Carcinoma, Renal Cell
Gastrointestinal Tract
Male
Mass Screening
Neoplasm Metastasis
Penile Neoplasms
Prognosis
Sensitivity and Specificity
Testicular Neoplasms
Urinary Bladder
Urinary Bladder Neoplasms
Urogenital Neoplasms*